Furthermore, we performed an experimental study to evaluate: a) the serum levels of GP73 in a cohort of biopsy-confirmed MASLD patients, and b) the diagnostic accuracy of GP73 to discriminate patients with MASH and significant or advanced fibrosis. The gene discussed is GOLM1; the disease is metabolic dysfunction-associated steatohepatitis.